Researchers reported a bioengineered viral platform that performs RNA editing in macrophages in vivo to treat sepsis, as published in Nature Communications. The system combines targeted viral delivery with chemogenetic control to edit transcripts within innate immune cells, aiming to modulate hyperinflammatory responses that drive sepsis mortality. The work offers a translational path for cell‑type‑specific RNA therapeutics that could be advanced toward preclinical safety and efficacy studies.